UroGen Pharma Ltd. (URGN)

NGM – Real vaqt narxi. Valyuta: USD

48.97

+1.85 (3.94%)

Bozor ochiq: Aug 12, 2026, 2:29 PM EDT

47.13

+0.02 (0.04%)

Oldingi bozordan keyin: Aug 11, 2026, 7:36 PM EDT

05.08.2026

Urogen Pharma Q2 Earnings Call Highlights

Urogen Pharma NASDAQ: URGN reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.9 million loss, or $1.05 per share, in the prior-year quarter.

05.08.2026

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

05.08.2026

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $1.05 per share a year ago.

05.08.2026

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103 Continued advancement of pipeline, with UGN-103 on track for NDA submission in the third quarter of 2026 and UGN-501 expected to begin a Phase 1 trial in the fourth quarter of 2026 Conference call and webcast held today at 10:00 AM ET PRINCETON, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Videolar

No Data

There is no data to display

Press-relizlar

05.08.2026

UroGen Pharma Ltd. (URGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

UroGen Pharma Ltd. (URGN)

Urogen Pharma Q2 Earnings Call Highlights

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Videolar

No Data

Press-relizlar

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Urogen Pharma Q2 Earnings Call Highlights

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Videolar

No Data

Press-relizlar

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Search stocks

UroGen Pharma Ltd. (URGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

UroGen Pharma Ltd. (URGN)

Urogen Pharma Q2 Earnings Call Highlights

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Videolar

No Data

Press-relizlar

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Urogen Pharma Q2 Earnings Call Highlights

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Videolar

No Data

Press-relizlar

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights